Targeted skin therapy Blueberry Therapeutics focuses on skin diseases including Onychomycosis, Tinea Pedis, Acne and Atopic Dermatitis, indicating an opportunity to position dermatology-focused partnerships, clinical trial collaborations, and co-development agreements with pharma stakeholders seeking innovative skin disease treatments.

Early-stage pipeline With emphasis on preclinical research and rapid progression to clinical proof-of-concept, there is potential to offer early-phase research services, translational collaborations, or sponsored preclinical programs to accelerate time-to-clinic for partner molecules.

Limited yet agile Small team size (2-10 employees) and a modern, agile development approach signal a fit for risk-sharing collaborations, milestone-based partnerships, and lightweight outsourcing models that leverage Blueberry’s flexible resourcing.

Funding readiness Recent funding and investors (NPIF/Maven) alongside a revenue stream under one million USD suggest opportunities to discuss strategic financing partnerships, grant co-development, or staged investment to scale successful candidates.

Clinical design focus Blueberry emphasizes smart, agile clinical designs to reduce costs and accelerate trials, presenting a compelling case for CRO partnerships, adaptive trial collaborations, and regulatory consulting services aligned to their development philosophy.